CEL-SCI enters 50/50 revenue-sharing partnership with Amarox for Multikine in Saudi Arabia

CEL SCI CORP

50%/50% net revenue share for Multikine sales in Saudi Arabia; Amarox exclusive distributor upon SFDA approval.
Amarox ranked #1 for SFDA critical/unavailable medicine applications for 3 consecutive years (2022-2024).
Optional extension to GCC countries (Bahrain, Kuwait, Oman, Qatar, UAE). CEL-SCI retains all IP and global rights.
Partnership targets SFDA Breakthrough Medicine Designation for Multikine in head and neck cancer.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.7

CEL SCI CORP entered into a license with Amarox.

Action: entry
Agreement: license
Counterparty: Amarox

Exact text from the filing

the Company issued a press release, filed as Exhibit 99, concerning a strategic partnership, distribution, and revenue sharing agreement with Amarox for regulatory affairs, marketing and potential commercialization of Multikine (Leukocyte Interleukin, Injection) in the treatment of head and neck cancer in Saudi Arabia, with an optional extension for the Gulf Cooperation Council (GCC) countries including Bahrain, Kuwait, Oman, Qatar, and the United Arab Emirates.

View on SEC.gov

Browse all material agreements →

CEL SCI CORP filing history →

Source: SEC EDGAR

accession 0001654954-26-004910

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.